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Classification of invasive 
bloodstream infections 
and Plasmodium falciparum malaria 
using autoantibodies as biomarkers
Ralf Krumkamp1,2,9, Nicole Sunaina Struck1,2,9*, Eva Lorenz1,2, Marlow Zimmermann1,2, 
Kennedy Gyau Boahen3, Nimako Sarpong3, Ellis Owusu‑Dabo4, Gi Deok Pak5, Hyon Jin Jeon5, 
Florian Marks5,6, Thomas Jacobs7, Jürgen May1,2,8,9 & Daniel Eibach1,2,9
A better understanding of disease‑specific biomarker profiles during acute infections could guide 
the development of innovative diagnostic methods to differentiate between malaria and alternative 
causes of fever. We investigated autoantibody (AAb) profiles in febrile children (≤ 5 years) admitted to 
a hospital in rural Ghana. Serum samples from 30 children with a bacterial bloodstream infection and 
35 children with Plasmodium falciparum malaria were analyzed using protein microarrays (Protoplex 
Immune Response Assay, ThermoFisher). A variable selection algorithm was applied to identify the 
smallest set of AAbs showing the best performance to classify malaria and bacteremia patients. The 
selection procedure identified 8 AAbs of which IFNGR2 and FBXW5 were selected in repeated model 
run. The classification error was 22%, which was mainly due to non‑Typhi Salmonella (NTS) diagnoses 
being misclassified as malaria. Likewise, a cluster analysis grouped patients with NTS and malaria 
together, but separated malaria from non‑NTS infections. Both current and recent malaria are a 
risk factor for NTS, therefore, a better understanding about the function of AAb in disease‑specific 
immune responses is required in order to support their application for diagnostic purposes.
Differentiating malaria from alternative causes of febrile illnesses, in particular invasive bloodstream infections, is 
complex because of unspecific and overlapping disease symptoms. Reliable rapid diagnostic tests for malaria are 
available and in  use1. However, due to semi-immunity, asymptomatic parasitaemia is common in holo-endemic 
malaria regions, which impedes accurate diagnoses in the presence of co-infecting pathogens. Thus, a positive 
malaria rapid diagnostic test result does not rule out other concomitant febrile diseases. Recent studies on causes 
of fever in Ghana and Tanzania showed that half of the children with parasitaemia revealed other diagnoses apart 
from  malaria2,3. To address this challenge, the WHO recommends a combination treatment with broad-spectrum 
antibiotics and antimalarials for all cases of severe malaria in endemic settings, leading to high antimicrobial 
drug  usage4. A diagnostic test, which is able to distinguish between malaria, bacteremia or a co-infection would 
facilitate empiric treatment decisions without prescribing unnecessary antimicrobial medication.
It has been shown that malarial infections lead to a range of characteristic immune responses, including 
hypergammaglobulinemia, polyclonal B cell activation and an increase in autoantibody (AAb)  production5. It 
was shown that healthy individuals living in malaria hot-spots possess higher AAb levels than healthy individu-
als from malaria-free zones within the same  country6–8. While AAbs are used for diagnosing several chronic 
inflammatory  diseases9–11, little is known about their diagnostic potential in malaria, bacteremia or their use in 
the differential diagnoses of malaria from other infectious diseases.
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The aim of the analysis is to identify the smallest set of AAbs capable to classify children with malaria or bacte-
rial bloodstream infection. Using protein microarrays spotted with more than 9000 recombinant human proteins, 
we screened the serum of children infected with Plasmodium falciparum or with bacterial bloodstream infections.
Results
Patients with bacteremia, malaria and controls were age and sex matched with a median age of 2 years (IQR 1–3) 
and 49% (n = 37) females in the study group. The majority of study participants were sampled during the rainy 
season (controls: 10 [100%], malaria: 30 [86%] and bacteremia 28 [93%]). The median parasite count in malaria 
patients was 181,670/µl (IQR 32,692–324,725) and the most frequently identified pathogen in the bacteremia 
group was NTS (n = 13; 43%) (Table 1).
Of the initial 9345 proteins on the array, 439 (5%) were excluded from the analysis because of elevated negative 
control values. Furthermore, 291 (3%) proteins were excluded because of batch effects, which left 8615 (92%) 
for further analyses. The distribution of AAbs ordered by their respective negative control values are shown in 
the Supplemental Fig. S1.
The proportion of AAbs per study participant with signal measurements above the respective AAb-median 
was assessed for controls, bacteremia patients and malaria patients. These values allow a relative quantification 
of high measurements in fluorescence intensities across disease groups (Supplemental Fig. S2). The median 
proportion of strong signals per observation was highest in malaria patients (71%; IQR 35–92), compared to 
bacteremia patients (40%; IQR 16–70) and controls (10%; IQR 5–16), which suggests higher fluorescence signals 
within the malaria group. There was no association between signal intensity and parasitaemia. However, among 
the bacteremia group, patients with NTS infections revealed a larger proportion of strong fluorescent signals 
compared to other bacterial species. Due to the low sample size, no further statistical analyses were applied.
AAb selection by random forest. Repeated random forest models were fitted to select the smallest set of 
AAbs with the best predictive accuracy. First, a random forest with all AAbs was calculated. Iteratively, 20% of 
markers with the lowest variable importance were removed and the models were recalculated. The full random 
forest model had a classification error of 42% and the median error over all iterative models was 31% (IQR 
26–32). The smallest classification error rate of 22% was observed in the 32nd model fitted with 8 AAbs. Selected 
AAbs are described in Table 2 and their variable importance is shown in Fig. 1. To evaluate the performance of 
the selected model, patient’s disease-classes were predicted. The prediction error in the malaria group was 14% 
and, by far, lower compared to the bacteremia group (30%). Subdividing the bacteremia group into NTS and 
non-NTS isolates (i.e. all other bacterial species) showed that 8 (62%) of the NTS, but only 1 (6%) of the non-
NTS patients were misclassified as malaria. Hence, the lower prediction accuracy in the bacteremia group was 
mainly due to NTS patients’ AAb profiles causing a misclassification as malaria.
The proximity analysis highlighted the relatedness among malaria and NTS patients. Three patient-clusters 
were established from random forest’s proximity data, which are shown in the multidimensional scaling (MDS) 
map in Fig. 2A. The distribution of diagnoses within the clusters is displayed as bar charts in Fig. 2B. The first 
cluster primarily contained malaria patients (n = 18; 86%) along with 3 (14%) NTS patients. The median parasite 
density in malaria patients was 257,386/µl (IQR 61,266–399,546). Also, the second cluster was dominated by 
malaria patients (n = 17; 59%), with 8 (28%) NTS and 4 (14%) non-NTS patients. Compared to cluster 1, the 
median parasite count of malaria patients was lower (median = 106,470/µl, IQR 22,143–262,150). Within the 
third cluster the majority of non-NTS patients (n = 3; 87%) were grouped, along with only 2 (13%) NTS and no 
malaria cases.
Autoantibody induction levels. Induction levels of the eight AAbs selected by random forest are shown 
in Fig. 3. For most markers, the median induction levels were lowest in controls, followed by non-NTS and 
NTS cases, and were highest in patients with malaria. Only in CCDC134 the control group showed a median 
induction level above cases with other bacterial species than NTS (non-NTS). In all AAb, the malaria group had 
the highest variability in the measured induction levels compared to the other groups. However, the individual 
Table 1.  Characteristics of study participants stratified by study group. IQR interquartile range, n sample size, 
NA not applicable.
Characteristics (statistics) Bacteremia (30) Malaria (35) Control (10)
Age in years [median (IQR)] 2 (1–3) 2 (1–3) 1 (1–3)
Female [n (%)] 15 (50) 17 (49) 5 (50)
Parasite count/µl [median (IQR)] NA 181,670 (32,692–324,725) NA
Bacterial isolate [n (%)]
Non-typhi Salmonella (NTS) 13 (43) NA NA
Salmonella Typhi 7 (23) NA NA
Streptococcus pneumoniae 5 (17) NA NA
Staphylococcus aureus 3 (10) NA NA
Acinetobacter spp. 1 (3) NA NA
Campylobacter spp. 1 (3) NA NA
3
Vol.:(0123456789)
Scientific Reports |        (2020) 10:21168  | https://doi.org/10.1038/s41598-020-78155-y
www.nature.com/scientificreports/
parasite count did not correlate with AAb induction levels. Categorization of selected AAbs according to the 
predicted function of their antigen (as outlined in Table 2) showed that 6 of 8 are in some way involved in signal-
ing (BTN2A2, CCDC134, FBXW5, GP9, IFNGR2, and AF6), while the other two are involved in inflammation 
(ODAM) and the cell cycle (HAUS8). Antigen localization showed that five of the eight AAb targets are intracel-
lular (FBXW5, HAUS8, TAF6), whereby two are also secreted into the extracellular environment (CCDC134, 
ODAM), and three targets are extracellular (BTN2A2, GP9, IFNGR2).
Robustness of study results. Robustness of the random forest selection approach was tested by repeating 
the selection algorithm 100 times. The median classification-error rate in the 100 selected models was 23% (IQR 
22%–23%), compared to 22% in the applied model. The smallest classification-error was most often measured in 
a model containing eight AAbs (n = 29, 29%), which is in line with the applied model. The smallest marker-set 
selected contained 3 markers and the largest 62. Figure 4 summarizes the classification-error distribution over 
the 100 algorithm runs, while the finally applied model selection algorithm is printed in red. In total, 85 different 
AAbs were identified by repeating the selection algorithm. Figure 5 shows the 10 AAbs most often selected by 
the repeated models. All eight markers identified by the applied algorithm belong to these 10 markers. Notably, 
IFNGR2 and FBXW5 were selected in all 100 model runs.
Table 2.  Autoantibodies selected by the random forest algorithm.
Antigen UniProt12 Function Category Location
Butyrophilin subfamily 2 member A2 (BTN2A2) Q8WVV5
Type 1 membrane protein, belongs to immunoglobu-
lin superfamily, structurally related to family of T cell 
regulators (B7 family) (PMID: 23000944)
Immune response, signaling Extracellular
Coiled-coil domain containing 134 (CCDC134) Q9H6E4
Secretory protein, role in transcriptional regulation 
and MAPK signal transduction through Raf-1/MEK/
ERK and JNK/SAPK pathways (PMID: 18087676)
Signaling Intracellular, secreted
F-box -containing protein 5 (FBXW5) Q969U6
Substrate recognition component of E3 ubiquitin-
protein ligase complex (PMID: 10,531,035, 
19,232,515)
Protein modification, signaling Intracellular
Glycoprotein IX (platelet) (GP9) P14770
Platelet surface glycoprotein, single-pass type I, 
part of receptor complex for von Willebrand factor 
(VWF) (PMID: 15,381,249)
Hemostasis, signaling Extracellular
Interferon gamma receptor 2 (IFNGR2) P38484
Single-pass type 1 membrane protein, forms IFN-γ 
receptor (together with IFNGR1), signal transduction 
in transcription regulation (PMID: 7673114)
Immune response, signaling Extracellular
Odontogenic, ameloblast associated (ODAM) A1E959 Tooth-associated epithelia protein, cancer related (PMID: 25911094) Inflammation Intracellular, secreted
8-Subunit Human Augmin Complex (HAUS8) Q9BT25
Protein complex required for mitotic spindle assem-
bly and centrosome integrity (PMID: 19427217, 
19369198)
Structure, cell cycle regulation Intracellular
Transcription initiation factor TFIID subunit 6 
(TAF6) P49848
Component of transcription factor IID complex 
(PMID: 15601843) Signaling Intracellular
Figure 1.  Variable importance of the eight autoantibodies based on the selected random forest model. 
Identifiers: FBXW5 F-box-containing protein 5, IFNGR2 Interferongamma receptor 2, HAUS8 8-Subunit 
Human Augmin Complex, ODAM Odontogenic, ameloblast associated, TAF6 Transcription initiation factor 
TFIID subunit 6, BTN2A2 Butyrophilin subfamily 2 member A2, CCDC134 Coiled-coil domain containing 134, 
GP9 Glycoprotein IX (platelet).
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Figure 2.  Cluster analysis. (A) Multidimensional scaling (MDS) map summarizing patient’s proximity in 
the final random forest model. Clusters are numbered and indicated by dashed lines. (B) The bars show the 
proportion of diagnoses allocated to the three clusters.
Figure 3.  AAb induction levels. The induction levels of the eight selected autoantibodies are shown for controls, 
non-NTS, NTS and malaria patients. Identifiers are explained in Table 1. RFU relative fluorescence unit, NTS 
non-Typhi Salmonella, non-NTS bacterial species other than NTS.
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Discussion
We established AAb profiles using protein microarrays for children with malaria or bacterial blood stream 
infections in order to identify disease specific induction patterns. These patterns were then tested for their 
ability to predict disease status, in order to identify AAb candidates capable to detect the underlying pathogen 
responsible for the acute infection. In general, most individuals have low autoantibody titers, while high levels 
Figure 4.  Classification error. The plot displays the robustness of the variable selection models by summarizing 
the distribution of classification errors over 100 marker selection algorithms. The x-axis shows the number of 
markers in a model and the y-axis the classification error of the respective random forest models. The change 
in classification error within the repeated marker selection algorithms are shown by the gray lines. The applied 
model is displayed by the red line. The boxplots show summary statistics about the number of AAb in finally 
selected models (y-axis) and the lowest classification errors (y-axis) in the repeated models.
Figure 5.  AAb selection model. Number of times where AAbs were selected in a repeated model. Markers 
selected by the applied model are colored dark gray and markers only selected in the repeated models are 
colored in white. Identifiers of AAbs not listed in Table 2: TEP4 (Transducin-like enhancer protein 4), KBTBD7 
(kelch repeat and BTB (POZ) domain containing 7).
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are associated with certain autoimmune diseases. Antinuclear antibodies (ANAs) for example are antibodies that 
recognize and bind to structures of the nucleus, like e.g. double-stranded  DNA13. Multiple studies over the years 
observed a high incidence of ANA in healthy individuals living in malaria-endemic areas of Africa, but a lack 
thereof in people from malaria-free areas within the same  country6,14,15. The occurrence of these ANAs together 
with high serum levels of anti-malaria antibodies led investigators to believe that this phenomenon might be 
malaria-induced7,8. Over the years, technological advances in biomedical research, broader autoantigen panels 
and high-throughput experiments in array format have now provided evidence for a greater number of AAbs 
to be associated with  malaria16–21.
The present analysis demonstrates an increased number of recognized self-antigens by AAbs, a higher signal 
intensity and response variability in patients with malaria compared to those with bacterial bloodstream infec-
tions. Especially children diagnosed with non-NTS isolates could be well separated from malaria patients. Our 
results allude to a resemblance between AAb induction profiles between malaria and NTS patients. Malaria and 
invasive NTS infections have a similar age distribution and their prevalence overlap  geographically22. Previous 
studies have demonstrated an increased risk for malaria patients to have a concomitant or subsequent invasive 
NTS  infection23,24. Inclusion criteria did not cover a history of fever dating back further than 48 h prior to enrol-
ment in the study. Therefore, it is possible that the NTS group, or a fraction thereof, rather represents AAb profiles 
of a recent malaria episode instead of a current NTS infection.
While it is accepted that infections may trigger AAb production, functional consequences and molecular 
mechanisms leading to autoimmunity remain unclear. Molecular mimicry, epitope spreading, bystander acti-
vation, polyclonal B cell activation are a few hypothesized mechanisms that could be  involved25,26. Recently, 
tumor-associated AAbs have expanded the field of cancer immunodiagnostics. In that context, it was noted that 
AAbs could be viewed as imprints of the ongoing immune response in the body. Even though only a few AAbs 
have been shown to be disease associated, different profiles have been linked with different diseases and could 
be useful as diagnostic markers apart from autoimmune  diseases27,28.
IFN-γ is a cytokine of the innate and adaptive immune system and has important functions in a number 
of immune-related processes. While IFN-γ plays a central role in controlling blood and liver stage malaria in 
humans and  mice29,30, it has also been shown to have an aggravating effect for the course of infection in  mice31,32. 
Transcriptional profiling of tissue cultures showed that the absence of IFN-γ receptor signaling led to an increase 
in parasite load in Toxoplasma gondii  infection33 but contributed to experimental cerebral malaria pathogenesis 
in  mice31,32,34.
Mendelian susceptibility to mycobacterial disease (MSMD) is a rare inherited condition where mutations 
in autosomal genes in pathways involving interferon-γ (as well as interleukin-12, and tumor necrosis factor α, 
TNF-α) cause a primary immunodeficiency and predisposes individuals to a wide range of infections, includ-
ing  NTS35,36. Autoantibodies against cytokines were found in the course of MSMD research, where anti-IFN-γ 
autoantibodies seemed to mimic inborn errors and interfere with IFN-γ signaling and correlate with dissemi-
nated opportunistic infections, including  Salmonella37.
The other selected candidate was FBXW5, a member of the family of F-box proteins that make up one of the 
four subunits of the ubiquitin protein ligase complex (also called SCF complex), which in turn plays a role in 
protein  degradation38. It contributes to the substrate specificity of the SCF complex and is also essential for its 
regulating during the cell  cycle39. Despite its basic molecular function, nothing much is known with respect to its 
role in infection. It will be crucial to validate our findings and further elucidate the (diagnostic) role of FBXW5 
in malaria or infections in general.
The large number of AAbs, in combination with the limited number of patient samples, is likely to produce 
chance findings. Thus, the current analysis is of exploratory nature and does not allow to determine the predictive 
power of particular AAbs under study or to select combinations of markers to be applied in a clinical setting. The 
eight candidates identified in this analysis need to be confirmed with well-characterized patient samples from an 
independent study in order to determine their diagnostic potential. A general limitation of serological testing 
in acute infections is the fact that disease-specific antibodies need several days after the onset of fever before 
being detectable in peripheral  blood40. In addition, antibody decay is lower than parasite clearance rates. Chronic 
exposure in malaria-endemic regions leads to a constant background seroprevalence, which limits serological 
tests in their sensitivity and specificity for diagnostics in acute  infections41,42. Further, the lack to distinguish 
patients with NTS from patients with malaria is a serious limitation with negative consequences for differential 
diagnostics in malaria endemic settings.
The current study showed different AAb induction profiles in children diagnosed with malaria or bacteremia, 
whereby bacteremia cases infected with bacterial species other than NTS showed a distinct AAb pattern com-
pared to malaria patients. In order to improve differentiation between malaria and NTS, better defined patient 
groups, e.g. with data about recent malaria infections, would be necessary. Taken together, this study identified 
candidates, which should be subject to further investigation. A validation of our prediction models is a promising 
next step in the development towards a new pathogen specific rapid diagnostic test.
Materials and methods
Ethics statement and informed consent. The study was performed in accordance with the relevant 
Ghanaian and German guidelines and regulations, and with the Declaration of Helsinki. Ethical approval for the 
study had been obtained from the Committee on Human Research, Publications, and Ethics, School of Medical 
Science, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana (Reference number: 
CHRPE/101/09) and the Institutional Review Board (IRB) of the International Vaccine Institute. Written inform 
consent was obtained from the participants. All parents or legal guardian were informed about the study’s pur-
pose and procedures, and provided written informed consent prior to enrollment.
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Study area, study group. Recruitment took place between February 2010 and May 2012 in the framework 
of a pediatric fever  study43. Serum samples from 65 children (≤ 5 years of age) admitted to the children’s ward 
of the Agogo Presbyterian Hospital (APH) in Ghana with fever (≥ 38 °C) were used for this study. Thirty-five 
children had P. falciparum parasitaemia and a negative blood culture, while 30 children had bacteremia with a 
negative malaria slide. As control group, asymptomatic children without fever and no signs of infection were 
selected and sampled in the frame of another fever  study2 at vaccination clinics in the surroundings of the APH. 
Data from control children were displayed as reference values, however not used in the classification analy-
sis, because the low sample size does not allow to predict a third outcome group. Children in all groups were 
matched by age and sex.
APH is a district hospital with 250 beds, situated in the Asante Akim North Municipality in Ghana. The region 
has a tropical climate and is highly endemic with P. falciparum.
Microbiological analysis. Blood cultures were performed with pediatric blood culture bottles (Becton 
Dickinson (BD) BACTEC Peds Plus/F) using an automated BACTEC 9050 Blood Culture System (BD, Franklin 
Lakes, NJ USA) as described  elsewhere43. Bacterial identification was achieved biochemically with API tests 
(bioMérieux, Marcy L’Etoile, France) and Salmonella isolates were serotyped following the White-Kauffmann-
Le Minor scheme. For data analysis bacteremia patients were classified as non-typhoid Salmonella (NTS; i.e., 
patients with invasive NTS) and non-NTS (i.e., causative agents of bacterial bloodstream infections other than 
NTS). Two independent slide readers conducted malaria microscopy on Giemsa stained thick and thin smears. 
In case of discrepancies in parasite counts, a third decisive reading by an additional reader was performed.
In order to investigate the autoantibody profile of the serum samples, protein microarrays were performed 
(ProtoPlex Immune Response Assay, ThermoFisher). Herein, 9345 human proteins were expressed as GST-tagged 
proteins in insect cells and purified under native conditions to maintain their native conformations and post-
translational  modifications44. Purified proteins were spotted on nitrocellulose-coated glass slides. These were 
blocked, washed and probed with a 1:500 dilution of selected human serum samples. A negative control assay 
incubated with buffer instead of serum served as a negative control to exclude non-specific interactions from the 
analysis. Alexa Fluor 647-conjugated goat anti-human IgG antibodies were used for detection and array signals 
were read using a Tecan PowerScanner fluorescent microarray scanner. The resulting signals were equated with 
AAb profiles. Relative Fluorescence Units (RFU) for each spot on the array was determined using GenePix 7 
software (Molecular Devices LLC, CA, USA) and signals were analyzed as described below.
Data analysis and statistical methods. Pre-processing steps were applied to prepare data for analysis. 
Background correction was conducted using the normal-exponential convolution method. Negative control val-
ues, which capture the fluorescence intensity of a marker without serum, were evaluated. Markers with negative 
control values above the  95th-percentile of the overall negative control distribution were deemed unspecific and 
excluded. Markers were analyzed in two batches. Antigens that were not recognized by any serum samples in 
either of these batches were removed from the dataset. No further batch effects, like varying induction intensity 
levels among batches, were detected.
Random forest was applied to identify the smallest set of AAbs showing the best performance to classify 
malaria or bacteremia patients in our dataset. Random forest is an ensemble learning method based on multiple 
classification and regression trees. Classification trees were used in our analysis, since we categorized observations 
according to their respective diagnoses. Each tree within a forest is built using a random subset of observations, 
and a random subset of variables are applied to group observations at each split. Using this approach, low-biased 
and low correlated individual trees are established, over which the final result is averaged. Classification error is 
estimated internally each time a tree is constructed by predicting the so called out-of-bag (OOB) observations, 
which were not considered while constructing a tree. This prevents overfitting since internally training and test 
datasets are utilized. Random forest calculates a variable importance measure for each variable, which is the 
increase in classification error if values of a variable would be permuted  randomly45. Random forest shows very 
good classification performance in high dimensional data, i.e. when the number of variables exceeds the number 
of observations, and when most predictor variables are  noise46.
To select a set of AAbs with best classification performance we followed the selection approach as described 
by Díaz-Uriarte et al.47. In a first step we fitted a full random forest considering all AAbs and we kept the vari-
able importance data. Iteratively, the 20% of AAbs with the smallest variable importance were removed and the 
remaining variables were used to re-run random forest. Variable importance was not recalculated for predictor 
selection since this would cause overfitting. Finally, we selected the AAb set with the smallest OOB-classification 
error from the  model47.
The final model, fitted with the selected set of AAbs, was evaluated to identify clustering among study par-
ticipants. In random forest, the proximity of each observation-pair is computed based on the frequency cases 
occupy the same terminal node within trees, assuming that similar observations are likely to share a terminal 
node. The dimensions of the proximity matrix were reduced to two coordinates by multidimensional scaling 
(MDS) to visualize similarities between observations with a scatter plot. In order to partition patients into clus-
ters, we applied the k- medoids algorithm on the proximity matrix.
Random Forests were constructed with the following parameter setting: default number of variables con-
sidered per split (i.e., square root of the number of AAbs), each forest contained 20,000 trees and the reciprocal 
frequency of malaria and bacteremia patients was used to weight classes (i.e., malaria = 30, bacteremia = 35) to 
account for imbalanced outcome groups. Each tree was unpruned and could grow fully to the largest extend pos-
sible. Random predictor and observation allocation in random forest influence model results and consequently 
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the set of markers selected by the algorithm. Thus, the robustness of the selection procedure was evaluated by 
repeating the marker selection algorithm 100-times.
All analyses were performed with R (version 3.6.1) using the packages PAA (version 1.10) for AAb pre-proces-
sion, randomForest (version 4.6–14) to fit random forest models and cluster (2.10) to partitioning patient clusters.
Data availability
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information files).
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